









Markets
/
Stocks
/
nasdaq-itrm
/

Iterum Therapeutics PLC

ITRM

0.302USD

+0.017+5.89%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

14.80MMarket Cap

LossP/E TTM



Iterum Therapeutics PLC

0.302

+0.017+5.89%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Iterum Therapeutics PLC

Currency: USD Updated: 2026-02-06

Key Insights

Iterum Therapeutics PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Iterum Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

150 / 392

Overall Ranking

295 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Iterum Therapeutics PLC Highlights

StrengthsRisks

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Overvalued

The company’s latest PE is -0.42, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.86M shares, decreasing 57.20% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 81.69K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.500

Target Price

+1828.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Iterum Therapeutics PLC is 5.79, ranking 324 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.79

Change



Financials

6.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.48

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Iterum Therapeutics PLC's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Iterum Therapeutics PLC is 7.65, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.42, which is -100.00% below the recent high of 0.00 and -274.86% above the recent low of -1.57.

Score

Industry at a Glance

Previous score

7.65

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 150/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Iterum Therapeutics PLC is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 9.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.500

Target Price

+1828.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Iterum Therapeutics PLC

ITRM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Iterum Therapeutics PLC is 6.50, ranking 233 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.37 and the support level at 0.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.27

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Sell

RSI(14)

42.180

Neutral

STOCH(KDJ)(9,3,3)

24.903

Neutral

ATR(14)

0.038

High Vlolatility

CCI(14)

-104.292

Sell

Williams %R

74.199

Sell

TRIX(12,20)

-0.526

Sell

StochRSI(14)

47.003

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.309

Sell

MA10

0.317

Sell

MA20

0.325

Sell

MA50

0.365

Sell

MA100

0.504

Sell

MA200

0.704

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Iterum Therapeutics PLC is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.49%, representing a quarter-over-quarter decrease of 31.43%. The largest institutional shareholder is James Simons, holding a total of 81.69K shares, representing 0.15% of shares outstanding, with 74.55% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Apollon Financial LLC

250.25K

Squarepoint Capital LLP

443.97K

-2.82%

Dunne (Michael W)

241.00K

+2.55%

OneDigital Investment Advisors LLC

191.00K

+18.63%

Fishman (Corey N)

137.06K

CAPTRUST Financial Advisors

111.60K

+870.43%

Gen-Wealth Partners Inc

82.05K

Renaissance Technologies LLC

Star Investors

81.69K

-82.69%

Virtu Americas LLC

47.13K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Iterum Therapeutics PLC is 1.78, ranking 282 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.